Biomarkers of Inflammation and Endothelial Dysfunction in Patients With Myocardial Infarction With Non-obstructive Coronary Arteries
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Myocardial Infarction
- Sponsor
- Hospital Universitario Getafe
- Enrollment
- 400
- Locations
- 1
- Primary Endpoint
- Levels of endhotelial disfunction biomarkers
- Status
- Recruiting
- Last Updated
- last year
Overview
Brief Summary
Around 10% of patients with myocardial infarction (MI) present with nonobstructive coronary arteries (MINOCA) which pathophysiology is often uncertain. The aim of the study is to evaluate inflammation and endothelial dysfunction biomarkers in MINOCA patients during both acute and stable phases, comparing them with those with MI and obstructive coronary arteries (MICAD).
Detailed Description
Prospective observational study in patients with Myocardial Infarction (MI) divided into two groups: MI with obstructive coronary arteries (MICAD) and MI with non-obstructive coronary arteries (MINOCA). Levels of interleukin-6, tumor necrosis factor-alpha, high-sensitivity C- reactive protein, and asymmetric dimethylarginine will be determined at three time points: within the 24 hours from the onset of pain, discharge, and two months after MI. The association of biomarkers, normalized by peak troponin value, with the risk of MINOCA will be evaluated using logistic regression.
Investigators
maria jesus espinosa pascual
Cardiologist
Hospital Universitario Getafe
Eligibility Criteria
Inclusion Criteria
- •Patients admitted with Myocardial Infarction and undergo a coronariography
- •Patients must sign informed consent.
Exclusion Criteria
- •Patients who don´t sign informed consent
Outcomes
Primary Outcomes
Levels of endhotelial disfunction biomarkers
Time Frame: At three time points: within the 24 hours from the onset of pain, on the 5th day of admission, and two months after MI.
Levels of asymmetric dimethylarginine will be determined
Levels of high-sensitivity C-reactive protein (mg/L)
Time Frame: t three time points: within the 24 hours from the onset of pain, on the 5th day of admission, and two months after MI.
Levels of high-sensitivity C-reactive protein (mg/L) will be determined.
Levels of interleukin-6 (pg/ml) and tumor necrosis factor-alpha (pg/ml)
Time Frame: At three time points: within the 24 hours from the onset of pain, on the 5th day of admission, and two months after MI.
Levels of interleukin-6 (pg/ml) and tumor necrosis factor-alpha (pg/ml) will be determined.